免疫疗法生物标志物 2016：突破障碍。
Immunotherapy biomarkers 2016: overcoming the barriers.
机构信息
Genitourinary Malignancies Branch, Center for Cancer Research, NCI, 10 Center Dr., 13 N240, Bethesda, MD, 20892, USA.
Vaccine Branch, Center for Cancer Research, 41 Medlars Dr, Bldg 41 Rm D702D, Bethesda, MD, 20892, USA.
出版信息
J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.
Abstract
This report summarizes the symposium, 'Immunotherapy Biomarkers 2016: Overcoming the Barriers', which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cosponsored by the Society for Immunotherapy of Cancer (SITC) and the National Cancer Institute (NCI), focused on emerging immunotherapy biomarkers, new technologies, current hurdles to further progress, and recommendations for advancing the field of biomarker development.
摘要
本报告总结了于 2016 年 4 月 1 日在马里兰州贝塞斯达的美国国立卫生研究院举行的研讨会“免疫治疗生物标志物 2016：克服障碍”。该研讨会由癌症免疫治疗学会（SITC）和美国国立癌症研究所（NCI）共同主办，重点讨论了新兴的免疫治疗生物标志物、新技术、进一步进展的当前障碍以及推进生物标志物开发领域的建议。
相似文献
1
Immunotherapy biomarkers 2016: overcoming the barriers.免疫疗法生物标志物 2016：突破障碍。
J Immunother Cancer. 2017 Mar 21;5(1):29. doi: 10.1186/s40425-017-0225-6.
2
Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.第 31 届癌症免疫治疗学会（SITC）年会要点，2016 年。
J Immunother Cancer. 2017 Jul 18;5(1):55. doi: 10.1186/s40425-017-0262-1.
3
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.免疫治疗生物标志物 iSBTc-SITC/FDA/NCI 研讨会建议
Clin Cancer Res. 2011 May 15;17(10):3064-76. doi: 10.1158/1078-0432.CCR-10-2234. Epub 2011 May 10.
4
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.SITC/iSBTc 癌症免疫治疗生物标志物资源文件：在线资源和有用工具——在生物标志物发现的领域中的指南针。
J Transl Med. 2011 Sep 19;9:155. doi: 10.1186/1479-5876-9-155.
5
The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.癌症免疫治疗生物标志物学会工作组建议审查。
Semin Cancer Biol. 2018 Oct;52(Pt 2):12-15. doi: 10.1016/j.semcancer.2017.09.006. Epub 2017 Sep 22.
6
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.识别基线免疫相关生物标志物，预测免疫治疗的临床结局。
J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017.
7
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.第 25 届国际癌症生物治疗学会年会综述。
J Transl Med. 2011 May 12;9:60. doi: 10.1186/1479-5876-9-60.
8
Toward integrative cancer immunotherapy: targeting the tumor microenvironment.迈向综合癌症免疫疗法：靶向肿瘤微环境。
J Transl Med. 2012 Apr 10;10:70. doi: 10.1186/1479-5876-10-70.
9
Preamble to the 2015 SITC immunotherapy biomarkers taskforce.前言 2015 年 SITC 免疫治疗生物标志物工作组
J Immunother Cancer. 2015 Mar 24;3:8. doi: 10.1186/s40425-015-0052-6. eCollection 2015.
10
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art.SITC 2018 研讨会报告：免疫肿瘤生物标志物：最新进展。
J Immunother Cancer. 2018 Dec 4;6(1):138. doi: 10.1186/s40425-018-0453-4.
引用本文的文献
1
The effect of cuproptosis-relevant genes on the immune infiltration and metabolism of gynecological oncology by multiply analysis and experiments validation.通过多重分析和实验验证，探讨铜死亡相关基因对妇科肿瘤免疫浸润和代谢的影响。
Sci Rep. 2023 Nov 9;13(1):19474. doi: 10.1038/s41598-023-45076-5.
2
An immunogold single extracellular vesicular RNA and protein ( SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients.一种免疫胶体金单外泌体 RNA 和蛋白质（SERP）生物芯片，用于预测非小细胞肺癌患者对免疫治疗的反应。
J Extracell Vesicles. 2022 Sep;11(9):e12258. doi: 10.1002/jev2.12258.
3
Identification and Validation of Efficacy of Immunological Therapy for Lung Cancer From Histopathological Images Based on Deep Learning.基于深度学习从组织病理学图像中识别和验证肺癌免疫治疗的疗效
Front Genet. 2021 Feb 9;12:642981. doi: 10.3389/fgene.2021.642981. eCollection 2021.
4
The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack.预测免疫治疗反应的多种潜在生物标志物——大海捞针
Cancers (Basel). 2021 Jan 13;13(2):277. doi: 10.3390/cancers13020277.
5
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.SITC 癌症免疫治疗资源文件：生物标志物发现领域的指南针。
J Immunother Cancer. 2020 Dec;8(2). doi: 10.1136/jitc-2020-000705.
6
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges.癌症免疫治疗学会临床和生物标志物数据共享资源文件：第一卷——概念挑战。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001389.
7
Evaluation of the upregulation and surface expression of hypoxanthine guanine phosphoribosyltransferase in acute lymphoblastic leukemia and Burkitt's B cell lymphoma.急性淋巴细胞白血病和伯基特B细胞淋巴瘤中次黄嘌呤鸟嘌呤磷酸核糖转移酶的上调及表面表达评估
Cancer Cell Int. 2020 Aug 6;20:375. doi: 10.1186/s12935-020-01457-8. eCollection 2020.
8
A Serum-Induced Transcriptome and Serum Cytokine Signature Obtained at Diagnosis Correlates with the Development of Early Pancreatic Ductal Adenocarcinoma Metastasis.在诊断时获得的血清诱导转录组和血清细胞因子特征与早期胰腺导管腺癌转移的发展相关。
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):680-689. doi: 10.1158/1055-9965.EPI-18-0813. Epub 2018 Dec 7.
9
Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop.将放射肿瘤学纳入免疫治疗：ASTRO-SITC-NCI 免疫治疗研讨会会议记录。
J Immunother Cancer. 2018 Jan 29;6(1):6. doi: 10.1186/s40425-018-0317-y.
10
The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review.癌症免疫治疗生物标志物学会工作组建议审查。
Semin Cancer Biol. 2018 Oct;52(Pt 2):12-15. doi: 10.1016/j.semcancer.2017.09.006. Epub 2017 Sep 22.
本文引用的文献
1
Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.123种外周血人类免疫细胞亚群的分析：确定年龄差异以及健康供体与癌症患者之间在标准免疫细胞类型分析中未检测到的差异。
J Circ Biomark. 2016 Mar 10;5:5. doi: 10.5772/62322. eCollection 2016 Jan-Dec.
2
Systematic evaluation of immune regulation and modulation.系统性评估免疫调节。
J Immunother Cancer. 2017 Mar 21;5:21. doi: 10.1186/s40425-017-0223-8. eCollection 2017.
3
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.用于预测癌症免疫治疗反应的生物标志物的验证：第一卷- 分析前和分析验证。
J Immunother Cancer. 2016 Nov 15;4:76. doi: 10.1186/s40425-016-0178-1. eCollection 2016.
4
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.用于预测癌症免疫治疗反应的生物标志物的验证：第二卷 - 临床验证和监管考虑因素。
J Immunother Cancer. 2016 Nov 15;4:77. doi: 10.1186/s40425-016-0179-0. eCollection 2016.
5
Biomarkers immune monitoring technology primer: Immunoscore® Colon.生物标志物免疫监测技术入门：免疫评分®结肠癌
J Immunother Cancer. 2016 Sep 20;4:57. doi: 10.1186/s40425-016-0161-x. eCollection 2016.
6
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.与黑色素瘤中PD-1阻断获得性耐药相关的突变
N Engl J Med. 2016 Sep 1;375(9):819-29. doi: 10.1056/NEJMoa1604958. Epub 2016 Jul 13.
7
Immune Profiles to Predict Response to Desensitization Therapy in Highly HLA-Sensitized Kidney Transplant Candidates.预测高HLA致敏肾移植受者脱敏治疗反应的免疫谱
PLoS One. 2016 Apr 14;11(4):e0153355. doi: 10.1371/journal.pone.0153355. eCollection 2016.
8
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.NIBIT-M1 研究中接受伊匹单抗联合福莫司汀治疗的晚期黑色素瘤患者的免疫标志物和临床结局。
Oncoimmunology. 2015 Aug 12;5(2):e1071007. doi: 10.1080/2162402X.2015.1071007. eCollection 2016 Feb.
9
Immune monitoring technology primer: immunoprofiling of antigen-stimulated blood.免疫监测技术入门：抗原刺激血液的免疫分析
J Immunother Cancer. 2016 Mar 15;4:18. doi: 10.1186/s40425-016-0122-4. eCollection 2016.
10
Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers.免疫结构、免疫评分和恶性细胞分子亚群在癌症预后和治疗分类中的应用。
Adv Immunol. 2016;130:95-190. doi: 10.1016/bs.ai.2015.12.002. Epub 2016 Jan 29.
Zotero 插件